Evidence for antibody as a protective correlate for COVID-19 vaccines.
Earle KA, Ambrosino DM, Fiore-Gartland A, Goldblatt D, Gilbert PB, Siber GR, Dull P, Plotkin SA. · 2021
Read Evidence for antibody as a protective correlate for COVID-19 vaccines. by Earle KA, Ambrosino DM, Fiore-Gartland A, Goldblatt D, Gilbert PB, Siber GR, Dull P, Plotkin SA. (2021) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc8142841.txt.
Description
Earle and co-authors ask whether antibody levels can stand in for vaccine protection against COVID-19. They compare efficacy data with lab antibody measures for seven vaccines. The studies came from varied places, assays, and vaccine platforms.
Once antibody levels were scaled to human convalescent sera, the links were strong. Neutralizing antibody levels tracked efficacy, and binding antibody levels tracked it still more closely. The authors also draw on natural history work and animal models. They conclude that antibody measures after vaccination can support a correlate of protection. That finding could speed approval of new vaccines when large trials are not feasible.
Catalog record
| CREATOR | Earle KA, Ambrosino DM, Fiore-Gartland A, Goldblatt D, Gilbert PB, Siber GR, Dull P, Plotkin SA. |
|---|---|
| YEAR | 2021 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 20 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |